Table 1 Clinical and histopathological patient characteristics

Sex

male

50 (64.1%)

0

7 (87.5%)

57 (53.8%)

female

28 (35.9%)

18 (100%)

1 (12.5%)

47 (46.2%)

Age diagnosis BM [years]

median

58.1

46

54.5

57

range

44–77

28–73

44–69

28–77

KPS preoperative (BM)

median

80

70

75

80

range

40–100

60–100

10–100

10–100

not available

1 (1.3%)

0

0

1 (0.9%)

Graded Prognostic Assessment

median

2.5

2

2

2.5

range

0.5-4

1–4

1–3

0.5-4

Year of BM diagnosis

1990–2000

15 (19.2%)

3 (16.7%)

5 (62.5%)

23 (22.1%)

2001–2010

33 (42.3%)

6 (33.3%)

3 (37.5%)

42 (40.4%)

2011–2020

30 (38.5%)

9 (50.0%)

0

39 (37.5%)

Immunohistochemistry

ER positive

8 (44.4%)

8 (7.7%)

PR positive

4 (22.2%)

4 (3.8%)

HER2 positive

3 (16.7%)

3 (2.9%)

Histopathology

Adenocarcinoma

61 (78.3%)

61 (58.7%)

Squamous Cell Carcinoma

14 (17.9%)

14 (13.5%)

Large Cell Carcinoma

3 (3.8%)

3 (2.9%)

Ductal

15 (83.3%)

15 (14.4%)

Lobular

2 (11.1%)

2 (1.9%)

Adenocystic

1 (5.6%)

1 (0.9%)

Clear Cell Carcinoma

8 (100%)

8 (7.7%)

Subtypes

Luminal

8 (44.4%)

8 (7.7%)

HER2

1 (5.6%)

1 (0.9%)

TNBC

9 (50%)

9 (8.6%)

Grading

G1

1 (1.3%)

1 (5.6%)

0

2 (1.9%)

G2

23 (29.5%)

5 (27.7%)

5 (62.5%)

33 (31.7%)

G3

26 (33.4%)

12 (66.7%)

0

38 (36.6%)

G4

1 (1.3%)

0

2 (25.0%)

3 (2.9%)

unknown

27 (34.5%)

0

1 (12.5%)

28 (26.9%)

Staging at BM diagnosis

Synchronous BM

26 (33.4%)

1 (5.6%)

1 (12.5%)

28 (26.9%)

Multiple BM

22 (28.2%)

8 (44.4%)

1 (12.5%)

31 (29.8%)

Concomitant extracranial metastasis

19 (24.4%)

12 (66.7%)

7 (87.5%)

38 (36.6%)

Neoadjuvant BM therapy

Chemotherapy

33 (42.3%)

16 (88.9%)

5 (62.5%)

54 (51.9%)

Radiotherapy

5 (6.4%)

0

1 (12.5%)

6 (5.8%)

Time-to-BM median [weeks]

median

44.8

126.2

118.1

57.1

range

0-320.0

0-281.3

3.6-520.6

0-520.6

Overall survival

median

62.4

28.0

61.7

53.7

from BM diagnosis range

3.0-787.1

0.9-164.4

1.9-262.9

0.9-787.1

[weeks] censored

12 (15.4%)

3 (16.7%)

0

15 (14.4%)